FY2025 EPS Estimates for Kura Oncology Decreased by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Brookline Capital Management decreased their FY2025 earnings per share (EPS) estimates for shares of Kura Oncology in a note issued to investors on Monday, January 5th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($2.87) per share for the year, down from their previous forecast of ($2.74). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s Q4 2025 earnings at ($0.61) EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $3.62 EPS and FY2029 earnings at $11.72 EPS.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $17.48 million.

KURA has been the subject of a number of other research reports. UBS Group raised their price target on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Barclays reiterated an “overweight” rating and issued a $28.00 price objective (up from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Wednesday, October 8th. Finally, Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Kura Oncology Price Performance

Shares of KURA stock opened at $9.55 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The company has a market capitalization of $831.02 million, a PE ratio of -3.85 and a beta of 0.25. The firm’s 50-day moving average is $10.74 and its two-hundred day moving average is $8.74. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $12.49.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 15,485 shares of the stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $173,122.30. Following the transaction, the insider owned 225,454 shares of the company’s stock, valued at approximately $2,520,575.72. This represents a 6.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kathleen Ford sold 6,902 shares of Kura Oncology stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $77,164.36. Following the completion of the transaction, the chief operating officer directly owned 105,373 shares of the company’s stock, valued at approximately $1,178,070.14. This represents a 6.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 68,343 shares of company stock worth $730,858. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its holdings in Kura Oncology by 0.9% during the 3rd quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock worth $1,061,000 after buying an additional 1,039 shares in the last quarter. Profund Advisors LLC raised its stake in shares of Kura Oncology by 11.1% in the third quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock valued at $220,000 after acquiring an additional 2,478 shares in the last quarter. Arizona State Retirement System boosted its holdings in Kura Oncology by 15.8% in the third quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock valued at $181,000 after purchasing an additional 2,802 shares during the period. The Manufacturers Life Insurance Company grew its stake in Kura Oncology by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock worth $175,000 after purchasing an additional 2,976 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after purchasing an additional 2,977 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.